On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
ThursdayApr 28, 2022 3:05 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Unlock Capabilities of Revolutionary DehydraTECH(TM) Platform

Lexaria Bioscience Corp. (NASDAQ: LEXX) is aware of the need to continuously improve its understanding of the capabilities and potential applications of its patented DehydraTECH(TM) drug delivery technology. This informs its long-held commitment to its applied research and development (“R&D”) programs. “So far, the company’s research journey has involved a series of controlled and well-designed in vitro preclinical testing and in vivo animal and human clinical studies…. Still, Lexaria is unrelenting in its pursuit of comprehensive datasets that would answer many questions the company expects to face from potential commercial partners or regulators and is, in fact, expanding its research.…

Continue Reading

FridayApr 22, 2022 3:45 pm

CannabisNewsBreaks – American Cannabis Partners Looking to Expand to Additional States

American Cannabis Partners (“ACP”), a sustainable Jamaican experience canna-business innovator, is among companies that will benefit from a proposed cannabis bill by Nancy Mace, designed to ease federal regulations on the substance. “Despite the House and Senate being controlled by the Democrats, Nancy Mace, a Republican representative from South Carolina, has said her proposed cannabis bill will get a hearing,” a recent article reads. “Cannabis companies around the country are watching this momentum closely, including American Cannabis Partners, which operates in Michigan and California. ACP is also in the process of exploring land acquisition and project development strategies for expanding…

Continue Reading

FridayApr 22, 2022 2:28 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Well Positioned for Opportunity

Flora Growth Corp. (NASDAQ: FLGC) has expanded its portfolio, which spans a range of verticals and diverse revenue streams, with growth largely driven through mergers and acquisitions (“M&As”). With M&As defining its 2021 calendar year, Flora Growth capitalized on global trends, which saw over 63,000 worldwide M&A transactions completed across all industries and sectors as companies sought new avenues for growth amid the pandemic, rising inflation and disrupted supply chains. With two recent acquisitions, Flora Growth “was able to add an estimated $35 million in revenues and $7 million EBITDA. For comparison, back in 2020, the company’s acquisitions generated $28…

Continue Reading

WednesdayApr 20, 2022 1:59 pm

CannabisNewsBreaks – Hero Technologies Inc. (HENC) Pursuing Diversification, Increased Share in Booming Colorado Market

Hero Technologies (OTC: HENC) anticipates expanding into the booming Colorado cannabis market via cultivation and dispensary operations through its wholly owned subsidiary, Mile High Green LLC. “Cannabis sales in the state broke another record last year, topping $2.22 billion in products sold, according to the Colorado Department of Revenue (https://cnw.fm/SFXzA). This figure ‘eclipses’ 2020 sales reaching upwards of $2.1 billion, which set a previous record,” a recent article reads. “Hero Technologies announced the formation of Mile High Green in March of last year, stating that the purpose of the subsidiary was to seek cannabis, land purchase and strategic acquisition opportunities in…

Continue Reading

MondayApr 18, 2022 2:39 pm

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Expanding Rare Cannabinoid Manufacturing Scale

InMed Pharmaceuticals (NASDAQ: INM), a rare cannabinoid drug developer, is expanding its product manufacturing scale, thanks largely to the acquisition of consumer-focused rare cannabinoids manufacturer BayMedica last year. “InMed’s most-recent Q2 financial statement reported revenues of $0.3 million from commercial sales of cannabichromene (‘CBC’) to the health and wellness market following the BayMedica acquisition. Since January, the company has also been selling cannabicitran (‘CBT’) to the health and wellness market on a B2B basis,” a recent article reads. “The company’s forward-looking focus on bringing new cannabinoid products to commercial scale anticipates scales of cannabidivarin (‘CBDV’) and tetrahydrocannabivarin (‘THCV’) in the…

Continue Reading

MondayApr 18, 2022 1:34 pm

CannabisNewsBreaks – Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) on ‘Solid Ground in 2022 and Beyond’

Red White & Bloom (CSE: RWB) (OTCQX: RWBYF), a company positioning itself to be one of the top three multistate operators in the United States in cannabis and hemp-derived product lines, has adopted a strategy anchored in operating a house of brands as it anticipates the commoditization of the cannabis market. “This is going to be a commoditized market, and our strategy is such that we are going to stand on our brands going forward. We just need to fortify what we are doing in the markets that we are in right now,” a recent article quotes RWB CEO Brad…

Continue Reading

WednesdayApr 13, 2022 1:09 pm

CannabisNewsBreaks – American Cannabis Partners Buoyed by Positive Look-Ahead Market Evaluations

American Cannabis Partners (“ACP”) is expected to see increasing opportunities to market its products as the cannabis landscape continues to shift, with growing numbers of states allowing some form of the substance and federal legislation examining changes in legal status. A recent article, which contains excerpts from a Hemp Industry Daily (“HID”) piece that looked at cannabis marketing trends for this year, documents that while Google is cracking down on advertising cannabis, other platforms like Twitter, Reddit and Quora are opening up. The article reads: “‘Of all the social media platforms, we have our eyes set on streaming platforms like…

Continue Reading

MondayApr 11, 2022 3:13 pm

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Taking Diverse Product Portfolio to New Markets

Flora Growth Corp. (NASDAQ: FLGC) recently announced the successful import of Mambe CBD-containing food and beverage products into the United States from Colombia. The move capitalized on a new law signed by Colombian President Ivan Duque, which provides the necessary regulatory framework for cannabis product use and export. “Our team anticipated this regulatory update and has been laying the necessary foundation to expand this new supply chain pathway allowing Flora to quickly bring our diverse product portfolio and low-cost cannabis inputs to new high-growth international markets,” a recent article quotes Flora Growth CEO Luis Merchan as saying. Flora Growth also…

Continue Reading

FridayApr 08, 2022 3:41 pm

CannabisNewsBreaks – Hero Technologies Inc. (HENC) Focusing on Expansion of Current Operations, Future Industry Growth

Hero Technologies (OTC: HENC) has made key acquisitions and investments that have played an essential role in its strategic business plan and operations. During a recent episode of the Bell2Bell Podcast hosted by Stuart Smith, company CEO Gina Serkasevich discussed HENC’s careful expansion moves. “In 2020, ‘both Highly Relaxing and the assets of V Brokers, under Veteran Hemp Co., were acquired,’ said Serkasevich. ‘Both of these entities gave Hero a foot in the door to establish itself as a cannabis player. Since then, our biggest advancement was becoming a majority stakeholder in BlackBox Systems and Technologies,’” a recent article reads.…

Continue Reading

FridayApr 08, 2022 2:37 pm

CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Hopes to Demonstrate DehydraTECH’s Superior Performance in Ongoing Epilepsy Research Program

Lexaria Bioscience Corp. (NASDAQ: LEXX) recently announced the beginning of the first phase of its epilepsy research program, EPIL-A21-1. “The research program will assess the seizure-inhibiting activity of cannabidiol (‘CBD’) administered via the company’s proprietary DehydraTECH(TM) technology, compared to the only FDA-approved CBD-based seizure medication…. The EPIL-A21-1 research program contains two main studies to be performed in rodents following the first phase – a pilot animal model that has already begun. The main studies are slated to commence in May/June and involve an acute seizure model induced by electrical stimulation and chemically induced seizure models,” a recent article reads. “Using…

Continue Reading

Official NewsWire Relationships

Alternative Products Expo Benzinga Cannabis Capital Conference Cannabis Business Summit & Expo 2019 Cannabis Drinks Expo Cannabis World Congress & Business Exposition MjMicro Conference New England Cannabis Network O'Cannabiz Conference & Expo

CannabisNewsWire Currently Accepts

Bitcoin

Bitcoin

Bitcoin Cash

Bitcoin Cash

Doge Coin

Dogecoin

Ethereum

Ethereum

Litecoin

Litecoin

USD Coin

USD Coin

Contact us: 303.498.7722